$1.100
+0.052 (+4.76%)收盤時
TPST 資訊
TPST 事件
Selling Stockholders Plan to Sell Up to 8.91M Shares
This filing relates to the offer and sale from time to time by the selling stockholders of up to 8.91M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
Rani Therapeutics Appoints Nicholas Maestas as CFO
Rani Therapeutics (RANI) announced the appointment of Nicholas Maestas as CFO, effective immediately. He succeeds Svai Sanford, who announced his departure in May to pursue another professional opportunity. He joins the company from Tempest Therapeutics (TPST), where he served as CFO and head of corporate strategy.
Selling Stockholders Plan to Sell 2.43M Shares of Common Stock
This filing relates to the offer and sale from time to time by the selling stockholders of up to 2.43M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
Tempest Therapeutics Achieves Milestone for TPST-2003
Tempest Therapeutics announced that it has achieved a milestone in the development of TPST-2003, Tempest's dual-targeting CD19/BCMA CAR-T therapy under development for the treatment of relapsed/refractory multiple myeloma. Earlier this month, Tempest's manufacturing partner, Cincinnati Children's Applied Gene and Cell Therapy Center, took delivery of the TPST-2003 lentiviral vector, a critical component used in the manufacturing of TPST-2003. This milestone supports Tempest's plans to initiate the first potentially registrational study to evaluate a dual-targeting CAR-T therapy in patients with rrMM, including patients who are experiencing extramedullary disease, later this year. Tempest recently announced that, as of a January 31 data cutoff, a total of 36 patients with rrMM had received one infusion of TPST-2003, including 24 patients in a prior Phase 1/2 investigator-initiated trial and 12 patients in the ongoing REDEEM-1 trial, representing one of the largest datasets evaluating a CD19/BCMA dual-targeting CAR-T therapy. As of the data cutoff, all six efficacy evaluable patients enrolled in the REDEEM-1 trial had achieved a complete response according to the International Myeloma Working Group uniform response criteria. Among 25 evaluable patients with measurable disease at baseline across both studies, the overall response rate was 100%. The IIT also demonstrated durable disease control, with median progression-free survival of 23.1 months across all patients and median PFS of 23.1 months in patients with EMD. Tempest plans to present the results of the REDEEM-1 trial and updated results from the IIT at a scientific meeting later this year.
Tempest Therapeutics Files to Sell 2.78M Shares of Common Stock
Tempest Therapeutics files to sell 2.78M shares of common stock for holders
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。